Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT ID: NCT02780583

Last Updated: 2024-08-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-05-15
• Study Completion Date: 2024-04-30

Brief Summary

The primary purpose of this study is to determine whether giving injections of anakinra is a safe and well tolerated treatment to give as an adjunct to standard prescribed treatment for patients who are admitted to the hospital with signs of severe inflammation (macrophage activation syndrome) that is potentially life-threatening. Anakinra is a commercially available product (Kineret™) approved for the treatment of rheumatoid arthritis; it is a replica of a naturally occurring protein called Il-1 receptor antagonist (IL-1ra), made by humans to inhibit and regulate the action of interleukin-1 (IL-1). IL-1 is a mediator of inflammation that when generated in excess amounts by immune system cells can result in severe dysfunction of multiple organs that can be life-threatening. The specific primary objectives of the study are to determine if giving anakinra results in no increased infection complications or mortality. Additional data will be collected to determine whether anakinra administration results in any other unanticipated side effects in this setting, and the effects of anakinra administration on inflammation markers, the overall dose of steroids required to treat the inflammation, and the length of hospital stay.

Detailed Description

Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequently fatal to the affected individual. This can occur in the setting of a number of different immune system disorders including, systemic lupus, systemic-onset juvenile arthritis, and adult-onset Still's disease. MAS can also occur in response to infection with certain viruses such as Epstein-Barr virus (EBV) and malignancies involving lymphocytes.

Because of the high fatality of MAS (>50%), a number of different treatments have been tried to manage this disorder, including use of high-dose steroids, immune suppressants such as cyclosporine, and cytotoxic chemotherapy treatments (etoposide) with variable success and/or severe complications of immune suppression (as may occur with etoposide). A number of recent case reports and case series have reported success using cytokine-blocking therapies such as anakinra in the treatment of MAS that is associated with systemic-onset juvenile idiopathic arthritis and adult Still's disease. Anakinra is a bio-engineered form of the naturally occurring interleukin-1 receptor antagonist (IL-1ra), that blocks the action of interleukin-1, one of the cytokines that is expressed and present in very high amounts in patients who have MAS. Anakinra/Il-1ra is an attractive treatment for patients presenting with clinical features of MAS because it has a relatively short half-life and is easy to administer by subcutaneous injection. In previous trials of its use in patients with clinical features of bacterial sepsis (fever, elevated heart rate, low/falling blood pressure) , it was shown that anakinra does not have a harmful effect but also did not appear to have any benefit with repect to the defined primary outcome of improved survival. However, a recent re-analysis of the data accumulated in these same previous sepsis trials (for which the primary defined outcome was survival) indicates that survival was actually increased in the subgroup of sepsis patients with features of MAS (ferritin elevations in excess of 2,000 ng/ml, signs of coagulopathy, and liver enzyme elevations) who were randomized to receive anakinra compared to the subgroup of sepsis patients with features of MAS who were randomized to receive placebo.

Previous doses of anakinra up to 3500 mg/day over 72 hours that were employed in the trials of adult patients with sepsis were noted to be well tolerated without increased adverse outcomes compared to patients randomized to placebo. Recent case reports have shown that doses up to 100 mg every 6 hours were efficacious and well tolerated in children with systemic onset juvenile arthritis complicated by refractory macrophage activation syndrome.

This study will be the first controlled study to confirm whether anakinra at dose of 10 mg/kg/day to a maximum of dose of 200 mg/day divided every 12 hours (for children ≤40 kg) or 5 mg/kg/day up to a maximum dose of 400 mg/day divided every 6 hours (children > 40 kg and adults) does not result in increased mortality or infection complications when administered in addition to current UAB standard of care treatment (corticosteroids) to children and adults hospitalized with suspected macrophage activation syndrome.

Conditions

Macrophage Activation Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

placebo

methylprednisolone intravenously, placebo shots every 6 hours

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo injection administered every 6 hours along with intravenous methylprednisolone

anakinra (Kineret)

methylprednisolone intravenously, anakinra shots every 6 hours

Group Type: EXPERIMENTAL

kineret

Intervention Type: DRUG

anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone

Interventions

kineret

anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone

Intervention Type: DRUG

placebo

placebo injection administered every 6 hours along with intravenous methylprednisolone

Intervention Type: DRUG

Other Intervention Names

Anakinra; normal saline

Eligibility Criteria

Inclusion Criteria

two or more Laboratory criteria: 1. Decreased platelet count (≤262 ×10 9/L) 2. Elevated levels of aspartate aminotransferase (>59 U/L) 3. Decreased white blood cell count (≤4.0 × 109/L) 4. Hypofibrinogenemia (≤2.5 g/L) or, three or more combined clinical/laboratory criteria:

1. Decreased platelet count (≤262 × 109/L)

2. Elevated levels of aspartate aminotransferase (>59 U/L)

3. Decreased white blood cell count (≤4.0 × 109/L)

4. Hypofibrinogenemia (≤2.5 g/L)

5. Central nervous system dysfunction (irritability, disorientation, lethargy, seizures, coma)

6. Hemorrhages (purpura, easy bruising, mucosal bleeding)

7. Hepatomegaly (≥3 cm below the costal margin or confirmed by imaging)

OR

2] No previous diagnosis of sJIA and serum ferritin > 2,000 ng/ml and 3 out of the following:

1. Bicytopenia with two of the following:

1. Absolute Neutrophil Count < 1,000,

2. Platelets < 100, 000/mm3,

3. Hemoglobin < 9 mg/dl

2. Fasting triglyceride >265 mg/dL

3. Splenomegaly

4. ALT OR AST > 120 IU/L (or > 2x upper limit of normal)

5. Fever with temp ≥ 101° F

6. Fibrinogen < 1.5 g/L (150 mg/dl) or INR > 1.5 or d-dimer > 500 ng/ml

-

Exclusion Criteria

1. Evidence of malignancy

2. Culture evidence of systemic bacterial infection at the time of screening

3. Known EBV viremia by PCR at time of screening (positive serologies are not an exclusion; results of EBV testing will not be necessary for enrollment, but may be ordered as part of the standard of care assessment to guide future management as results become available)

4. Previous treatment for the current MAS episode with corticosteroids, anakinra, tocilizumab, anti-TNF therapy or cyclosporine

5. <1 year of age

6. Family history of familial HLH

7. Evidence of any of the following

1. Creatinine at the time of screening > 2X ULN or > twofold increase from patient's baseline creatinine within past 3 months (if known)

2. Albumin < 1.5 at the time of screening

3. Mechanical ventilation at the time of screening

4. Hypotension requiring use of pressors at the time of screening

• Minimum Eligible Age: 1 Year
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

W Winn Chatham

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Walter W Chatham, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama Hospital

Randall Q Cron, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Alabama

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Countries

United States

References

Cron RQ, Chatham WW. The Rheumatologist's Role in COVID-19. J Rheumatol. 2020 May 1;47(5):639-642. doi: 10.3899/jrheum.200334. Epub 2020 Mar 24. No abstract available.

Reference Type: DERIVED

PMID: 32209661 (View on PubMed)

Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, Beukelman T, Atkinson TP, Cron RQ. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020 Feb;72(2):326-334. doi: 10.1002/art.41103. Epub 2019 Dec 26.

Reference Type: DERIVED

PMID: 31513353 (View on PubMed)

Other Identifiers

FWA00005960

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

SOBI_UAB01

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

F151008003

Identifier Type: -

Identifier Source: org_study_id